Yither biotech

简体中文
img
Your position:
Homepage
>
News
05-08

The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating.

Recently, the IND application for a Class 1 new drug— "Respiratory Syncytial Virus mRNA Vaccine" —jointly submitted by Ab&B Bio-Tech Co. Ltd. JS (Ab&B Bio) and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) was approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration.
The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating.
03-13

Ab&B Bio-Tech Co., Ltd. collaborates with Walvax Biotechnology Co., Ltd. to seamlessly connect the third-generation subunit influenza vaccine and embark on a new journey of going global

On March 13, 2026, Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) and its parent company Ab&B Bio Tech Co., Ltd. (Ab&B Bio) officially signed a strategic cooperation agreement for the overseas market of influenza virus subunit vaccines with Watson Biotech Hong Kong Limited (hereinafter referred to as "Watson Hong Kong") in Taizhou. Both parties announced that they will jointly promote Ab&B Bio's independently developed influenza virus subunit vaccine to set sail overseas. This is not only a milestone moment for Chinese vaccine companies to cooperate and build a healthy industry ecosystem, but also signifies that China will bring safer and more effective solutions to the global influenza prevention and control field.
Ab&B Bio-Tech Co., Ltd. collaborates with Walvax Biotechnology Co., Ltd. to seamlessly connect the third-generation subunit influenza vaccine and embark on a new journey of going global
03-04

Monkeypox mRNA Vaccine Secures FDA Clinical Approval, Trivalent Influenza Virus Subunit Vaccine Wins First Bid in Shanxi

Recently, Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) and its parent company Ab&B Bio Tech Co., Ltd. (Ab&B Bio) have achieved multiple breakthroughs in innovative vaccine research and commercialization. The independently developed monkeypox mRNA vaccine has obtained clinical trial approval from the US FDA and is the first and only domestically approved trivalent influenza virus subunit vaccine with full dose for the entire population. In response to the WHO's official release of recommended components for seasonal influenza vaccines in the Northern Hemisphere for 2026-2027, it has successfully won the bid in Shanxi Province. This marks a new milestone for Zhonghui Biotechnology in its internationalization journey, policy response speed, and market access capabilities.
Monkeypox mRNA Vaccine Secures FDA Clinical Approval, Trivalent Influenza Virus Subunit Vaccine Wins First Bid in Shanxi
02-26

Announcement of Pre increase in Performance for 2025 Released

Today, Yither Biotech (Shanghai) Co., Ltd (Yither Bio) and its parent company Ab&B Bio-Tech Co.,Ltd (Ab&B Bio) (hereinafter referred to as "Ab&B Bio", stock code: 02627.HK) have issued a pre-announcement of expected performance increase for the year 2025, based on a preliminary review of the unaudited key financial data of the company during the reporting period.
Announcement of Pre increase in Performance for 2025 Released
02-16

Ab&B Bio-Tech Co., Ltd. has been included in the Hang Seng Composite Index, and its recognition in the capital market continues to increase

Recently, Hang Seng Indexes announced the results of the quarterly review of the Hang Seng Index series as of December 31, 2025. Yither Biotech (Shanghai) Co., Ltd (Yither Bio) and its parent company Ab&B Bio-Tech Co.,Ltd (Ab&B Bio) (stock code: 02627.HK; hereinafter referred to as "Ab&B Bio") have been successfully included in the Hang Seng Composite Index due to their robust operating performance, standardized corporate governance, and continuously growing market capitalization. The relevant adjustments will be implemented after the market close on Friday, March 6, 2026, and take effect from Monday, March 9, 2026. This marks a further increase in the company's coverage and recognition in the Hong Kong capital market, as well as a further enhancement of its influence in the international capital market. The company is also expected to be included in the scope of investable stocks under the Shanghai and Shenzhen Stock Exchange's Hong Kong Stock Connect program.
Ab&B Bio-Tech Co., Ltd. has been included in the Hang Seng Composite Index, and its recognition in the capital market continues to increase
11-13

Trivalent and quadrivalent influenza virus subunit vaccines (adjuvants) have entered phase I clinical trials as scheduled

Recently, the Phase I clinical trials for a new type of vaccine, "Influenza Virus Subunit Vaccine (Adjuvant)", and "Tetravalent Influenza Virus Subunit Vaccine (Adjuvant)", jointly applied for by Yither Biotech (Shanghai) Co., Ltd (Yither Bio) and its company Ab&B Bio-Tech Co.,Ltd (Ab&B Bio), have been successfully initiated in Hubei. These two vaccine research and development achievements are steadily translating into company performance, and also mark a solid step forward in the company's subunit influenza vaccine product pipeline towards providing the most precise coverage for people of different ages and needs.
Trivalent and quadrivalent influenza virus subunit vaccines (adjuvants) have entered phase I clinical trials as scheduled
Pre
1
2
3
4
...
8
E-mail

E-mail

yue.peng@yitherbiotech.com

Whatsapp

Whatsapp

Whatsapp:+86-18521090810

TEL.

+86-021-61639751

TOP

Need more help?

Yither Biotech is striving for and committed to producing innovative and quality vaccines to contribute to the development of China’s biomedical industry and the wellness of Chinese and people around the world.

CONTACT

QUICK LINKS

PRODUCTS

SHARE

Copyright: Yither Biotechnology  Co. Ltd  Powered by:www.30.cn  SEO

Verification 沪ICP备2021028966号-1